

Health News / Latest Health News / Pharma

Dr. Reddy's announces the launch of Vasopressin inj (generic version of VASOSTRICT) in the U.S. Market

The VASOSTRICT® brand market had U.S. sales of approximately \$878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health.

ETHealthWorld • February 09, 2022, 23:15 IST



Hyderabad, India and Princeton, NJ, USA. February 9, 2022 - [Dr. Reddy's Laboratories](#) Ltd. today announced the launch of its authorized generic version of Par Pharmaceutical's [VASOSTRICT®](#) (vasopressin injection, USP) Vials in the U.S. Market approved by the [U.S. Food and Drug Administration](#)

(USFDA).

“We are pleased to provide this important authorized generic product to patients, especially in these difficult times of COVID-19,” says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories Inc.

The VASOSTRICT® brand market had U.S. sales of approximately \$878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health.

ADVERTISEMENT

Digital Renaissance in Fertility Care

ETHealthworld Fertility Conclave 2022

25 February 2022 @ 11:00 AM

Join ETHealthworld Fertility Conclave

[Register Now >](#)



Dr. Reddy's Vasopressin Injection, USP, is supplied in a carton of 25 single-dose vials each containing vasopressin 1 mL at 20 units/mL.

[Edit](#)

Follow and connect with us on [Twitter](#), [Facebook](#), [LinkedIn](#), [Youtube](#)

Pharma

vasostrict

u.s. food and drug administration

reddy s vasopressin injection

reddy s laboratories inc

Dr. Reddy's Laboratories

People who read this also read



'Charak Shapath' may replace Hippocratic Oath



Health Ministry issues revised guidelines for International travel



CCPA passes order for discontinuation of Sensodyne ads in India



NMC flags China travel rules, warns of med e-courses

Subscribe to our Newsletter

125000+ Industry Leaders read it everyday